ABOUT US
SIMPLIFYING CHRONIC CARE
Our Vision
At Anodyne Nanotech, we believe that breakthrough medicines require unique delivery systems to reach their full potential and provide the desired clinical outcomes. For hundreds of years, needles and syringes have been used to deliver medicine, and innovation is long overdue.
The HeroPatch is the first platform capable of efficiently delivering clinically meaningful doses of medicine in a tunable system to provide a better and more convenient alternative to cumbersome injections.
Together, we will redefine drug delivery.
Our Mission
Make the HeroPatch a reliable transdermal delivery system to simplify chronic care for all.
Meet The Team
Our Leadership
Jake Lombardo
Co-Founder & CEO
Jake has a unique combination of biomedical engineering experience and entrepreneurial acumen. He holds a B.S. of Biomedical Engineering from Union College and an M.Sc. of Innovation and Management from Tufts University. He couples this with leadership qualities developed over a lifetime of team sports to help set the direction of Anodyne.
Konstantinos Tzortzakis
Co-Founder & CBO
Konstantinos is an engineer turned entrepreneur. He holds a Diploma in Electrical and Computer Engineering from National Technical University of Athens and an M.Sc. in Innovation and Management from Tufts University, Boston, USA. Konstantinos has engineering and management expertise coupled with exposure in the US and Greece, making the alignment of interdisciplinary teams second nature.
Hojat Rezaei Nejad, PhD
Co-Founder & CTO
Hojat is a Physicist specialized in Microscale and Nanoscale physics. His work led to the discovery of several new physics that describe the behavior of nano-bubbles (NBs) and nano-droplets (NDs) in nanoscale and particles in microscale.
Dr. Nejad is also a known specialist in Micro/Nano Fabrication technologies. His work resulted in the development of innovative biomedical and lab-on-chip drug delivery and diagnostic devices. He is a former Assistant Professor of electrical and computer engineering at Tufts University was also a Pre- and Post-doctoral research fellow at Harvard-MIT Division of Health Sciences and Technology (HST). Dr. Nejad is a winner of several prestigious awards including Friedman Foundation Scholarships in Health Sciences. Dr. Nejad is from Shiraz, Iran.
Michael Elliott
COO
Experienced Chief Operating Officer in scaling Medical Device and Biotech start-ups, guiding them from concept to GMP manufacturing for clinical trials and commercialization. Prior to his entrepreneurial ventures, Michael held key leadership roles at BD (Becton Dickinson), across 8 locations and 6 business units. His work included driving successful product launches of devices and instruments that are currently used worldwide to deliver healthcare as well as stewardship with overseeing global production volumes ranging from hundreds of millions to billions annually. Michael holds an MBA from MIT and a Mechanical Engineering Degree from BYU.
Chirag B. Shah
VP R&D and Product Development
Chirag is a results-oriented leader with significant experience in R&D, Product Development, Quality and Operations. He has held various leadership positions at Arch Therapeutics, Medtronic (Covidien), Biolink and C.R. Bard. He has an excellent record in establishing collaborations and fostering innovative customer focused teams. Dr. Shah earned a PhD from University of Rhode Island and Executive Leadership Certificates from Cornell and MIT.
Board of Directors
Jeff Mihm
Jeff Mihm previously served as the CEO of Noven Pharmaceuticals, a fully-integrated pharmaceutical company and leader in the field of transdermal drug delivery. During his tenure as CEO, Noven gained FDA approval of a novel transdermal prescription patch product, transformed its manufacturing and quality systems and implemented a new strategic direction for the company. Mr. Mihm has significant experience with strategic partnerships and licensing transactions, including through Noven’s long-running joint venture with Novartis. Mr. Mihm played an integral role in the $428 million sale of Noven to Hisamitsu Pharmaceuticals. He currently serves as the Executive-in-Residence at the College of Pharmacy and the McCombs School of Business at the University of Texas at Austin, where he also teaches management strategy and global regulatory strategy.
Vikram Lamba
Vikram Lamba brings over 30 years of executive leadership and business development experience in global healthcare, with key roles across large pharmaceutical companies and innovative startups. He was previously CEO of Zosano Pharma, where he led a $425 million deal with Eli Lilly centered on microneedle technology and successfully guided the company through its IPO. Earlier in his career, he held leadership positions in M&A and corporate development at Bayer AG, including serving as Director of M&A.
Peter Savas
Mr. Savas brings over 30 years of experience in executive leadership positions across life sciences. He was CEO of Alseres Pharmaceuticals, Inc., Chairman and CEO of Aderis Pharmaceuticals, developer of the Neupro® transdermal patch marketed worldwide to treat Parkinson’s disease and Restless Legs Syndrome and Chairman and CEO of Unisyn, a cGMP contract manufacturer of biologics for clinical trials. Peter also held executive and operating leadership positions with Bristol Myers, Waters, Millipore, Genex and Zymark. With a personal mission for entrepreneurism and pursuing advancement in neurologic science, Peter bridges strategic and operational healthcare experience with broad access to industry, academia, regulatory and capital markets leaders. Peter holds a BS in Chemistry from Syracuse University and is credentialed as a Professional Director by the American College of Corporate Directors.
Michael Singer, MD, PhD
Dr. Michael Singer is a graduate of Yale University, where he earned his B.S. in Biology, M.D., and Ph.D. in Neuroscience. He is currently Co-Founder and CSO at Cartesian Therapeutics. Prior to that, he was Director of Translational Medicine at Novartis. Dr. Singer was also Co-Founder and CSO at HealthHonors Corporation and Topokine Therapeutics where they were acquired by Healthways and Allergan, respectively. He is a successful serial entrepreneur, healthcare investor, and physician-scientist with a background in transdermal drug delivery.
Konstantinos Tzortzakis
Konstantinos is an engineer turned entrepreneur. He holds a Diploma in Electrical and Computer Engineering from National Technical University of Athens and an M.Sc. in Innovation and Management from Tufts University, Boston, USA. Konstantinos has engineering and management expertise coupled with exposure in the US and Greece, making the alignment of interdisciplinary teams second nature.
